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ABSTRACT
Mixed lymphohematopoietic chimerism can be induced in mice with bone marrow transplantation (BMT) after a
nonmyeloablative preparative regimen that includes cyclophosphamide, anti–T-cell antibody therapy, and thymic
i rradiation. These mixed chimeras are resistant to the induction of graft-versus-host disease (GVHD) after delayed
donor leukocyte infusions (DLIs), despite a potent lymphohematopoietic graft-versus-host reaction that convert s
the mixed chimeric state to a full donor one. Based on this animal model, we initiated a trial of nonmyeloablative
therapy with HLA-matched or -mismatched donor BMT and DLI for re f r a c t o ry hematologic malignancies. Tw e n t y -
one of 36 patients enrolled in this trial received a genotypically (n = 20) or phenotypically (n = 1) HLA-matched
donor transplant; results re p o rted here are for those patients only. Preparative therapy consisted of cyclophos-
phamide in doses of 150 to 200 mg/kg; peritransplant antithymocyte globulin; thymic irradiation (in patients who
had not received previous mediastinal radiation therapy); and cyclosporine. Eighteen of 20 evaluable patients devel-
oped persistent mixed lymphohematopoietic chimerism as defined by >1% donor peripheral white blood cells until
at least day 35 posttransplantation. Ten patients received prophylactic DLI beginning 5 to 6 weeks after BMT for
conversion of mixed chimerism to full donor hematopoiesis and to optimize a graft-versus-leukemia effect. Four-
teen of 20 evaluable patients (70%) achieved an antitumor response; 8 of these responses were complete, and 6 were
p a rtial. Of the 8 evaluable patients who received prophylactic DLI, 6 showed conversion to full donor chimerism.
Five of the 9 evaluable patients (56%) who received prophylactic DLI achieved a complete response, compared with
3 of 11 patients (27%) who did not receive prophylactic DLI. Currently 11 patients are alive, and 7 of these are fre e
of disease pro g ression at a median follow-up time of 445 days (range, 105-548 days) posttransplantation. Tr a n s p l a n-
t a t i o n - related complications included cyclophosphamide-induced cardiac toxicity in 3 of 21 patients (14%) and
grade II or greater GVHD in 6 patients (29%). One patient (5%) died from a complication of BMT, and 1 patient
(5%) died from GVHD after 2 prophylactic DLIs were given for conversion of chimerism. In summary, mixed lymp h o-
hematopoietic chimerism was re p roducibly induced after a novel nonmyeloablative preparative regimen incorporat-
ing chemotherapy, peritransplant antithymocyte globulin, and thymic irradiation, allowing for early administration
of DLI in 10 of 21 patients. After treatment, striking antitumor responses were observed in the majority of patients
with chemotherapy-re f r a c t o ry hematologic malignancies.
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INTRODUCTION
Mixed lymphohematopoietic chimerism can be induced
in several animal models using myeloablative pre p a r a t i v e
regimens and mixed autologous (or syngeneic) and allo-
geneic marrow transplantation [1,2] or, after nonablative
p reparative regimens, using peritransplant anti–T-cell thera p y
[3-6]. In a murine model established by Pelot et al. [7],
mixed chimerism was induced across full major hist o c o m-
patibility complex barriers after a preparative regimen that
included cyclophosphamide, monoclonal anti–T-cell anti-
body therapy, and thymic irradiation. These mixed chimeras,
as well as mixed chimeras produced with earlier regimens [8],
w e re resistant to the induction of graft-versus-host disease
(GVHD) after delayed donor leukocyte infusions (DLIs),
despite a potent lymphohematopoietic graft-versus-host
reaction that converted the mixed chimeric state to a state of
full donor hematopoiesis. These results suggest that graft-
versus-leukemia (GVL) effects might be achieved without
development of GVHD via the initial induction of mixed
chimerism followed by delayed DLI.
In clinical bone marrow transplantation (BMT), tran-
sient mixed lymphohematopoietic chimerism occurs
c o mmonly after allogeneic transplantation. The re p o rt e d
incidence appears to be dependent on the sensitivity of the
chimerism assay used, with a higher likelihood of host cell
detection by polymerase chain reaction–based analyses than
by conventional cytogenetic assays [9-14]. Mixed chimerism
has been shown to be associated with less intensive (particu-
larly non–total body irradiation [TBI]-containing) prepara-
tive regimens and likely reflects increased host stem cell sur-
vival [15,16]. More o v e r, in some clinical series, an
association has been seen between mixed chimerism and a
reduced incidence of acute GVHD [9,11,17-19]. 
In an effort to reduce morbidity and mortality after con-
ventional allogeneic BMT, several investigators re c e n t l y
have used nonmyeloablative preparative regimens to achieve
alloengraftment. Although data re g a rding chimerism in
these studies are incomplete, it appears that in the majority
of cases, full or nearly full allogeneic chimerism was
achieved [20-22]. Based on the principle of lessened mor-
bidity accompanying nonmyeloablative conditioning ther-
apy, the potential GVHD modulatory effect of mixed lym-
phohematopoietic chimerism, and the attempt to capture
the potent cell-mediated antitumor effects of delayed donor
leukocyte infusions [23-25], we conducted a pilot trial of
nonmyeloablative therapy with BMT and DLI for patients
with refractory hematologic malignancies.
PATIENTS AND METHODS
Pa t i e n t s
Thirty-six patients with chemotherapy-refractory hema-
tologic malignancies were enrolled in a clinical trial con-
ducted at Massachusetts General Hospital (MGH) in
Boston. The trial involved nonmyeloablative conditioning
therapy followed by HLA-matched or -mismatched allo-
geneic BMT for the induction of mixed chimerism. The
p re l i m i n a ry results for the recipients of a 1- or 2 - a n t i g e n –
mismatched donor transplant have been published [26].
Only the results for the 21 patients who received a genotypi-
cally (n = 20) or phenotypically (n = 1) HLA-identical donor
transplant are reported here. All patients were treated under
the auspices of a protocol approved by the MGH Subcom-
mittee for Human Studies. Demographic characteristics for
the 21 HLA-matched recipients are described in Table 1.
Eligibility criteria for transplantation included a diagnosis
of chemotherapy-re f r a c t o ry hematologic malignancy, defin e d
as achievement of less than a partial response or disease pro-
g ression during salvage chemotherapy or relapse after autolo-
gous stem cell transplantation; Eastern Cooperative Oncology
G roup (ECOG) perf o rmance status of 0, 1, or 2; age ≤65 years;
and adequate organ function (as specified by the pro t o c o l ) .
Patients and their donors were typed for HLA-A and HLA-B
using standard serologic techniques and for HLA-DR using
sequence specific primer (SSP)- or sequence specific oligonu-
cleotide probe (SSOP)-based analyses. By virtue of their dis-
ease status and previous therapy (eg, an autologous stem cell
transplant), patients were believed to have a prohibitively high
risk of mortality after conventional allogeneic stem cell trans-
plantation or a very high risk of posttransplantation re l a p s e .
Conditioning Therapy
Conditioning therapy consisted of cyclophosphamide
50 mg/kg per day (with dosing based on actual or ideal
body weight, whichever was less), administered intra-
venously for 3 (n = 14) or 4 (n = 7) consecutive days on
transplant days –6 or –5 through –3. Thymic irr a d i a t i o n
(700 cGy) was given on day –1 in patients who had not
received previous mediastinal radiation therapy (n = 13)
and antithymocyte globulin (ATG) 30 mg/kg per day (n =
4) on days –2, –1, and 1 or 15 mg/kg per day (n = 17) on
days –1, 1, 3, and 5. Intravenous cyclosporine was begun
on day –1 at a dose of 5 mg/kg using continuous infusion
over 20 hours daily. On transplant day 4, the daily cyclo-
sporine dose was reduced to 3 mg/kg. When patients were
Table 1. Patient Characteristics*
No. of patients 21











Genotypically HLA identical 20
Phenotypically HLA identical 1
No. of patients with chemotherapy-refractory disease 20/21†
No. of patients who had received a previous 3
autologous stem cell transplant
*ALL indicates acute lymphoblastic leukemia; AML, acute myeloid
leukemia;  CLL, chronic lymphocytic leukemia; MM, multiple
myeloma; NHL, non-Hodgkin’s lymphoma.
†One patient was in untreated relapse after autologous peripheral
blood stem cell transplantation.
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able to tolerate oral medication, cyclosporine was changed
to oral administration at a dose of 6 mg/kg every 12 hours. 
Bone Marrow Collection and Infusion
Bone marrow was procured in the operating room from
donors under an epidural or general anesthetic. A targ e t
number of 3 × 108 nucleated cells per kg of recipient body
weight was sought. Five patients were recipients of marrow
with a minor or major ABO incompatibility. In the case of
minor ABO incompatibility (n = 1), plasma was re m o v e d
f rom donor marrow before transplantation. In the case of
major ABO incompatibility (n = 4), red blood cells were
depleted from the donor bone marrow using a CS-3000 cell
separator (Baxter-Fenwal, Round Lake, IL). Bone marro w
was infused at a rate of 300 to 500 mL/h.
Donor Leukocyte Collection and Infusion
In the absence of acute GVHD (or suspected GVHD),
patients were eligible to receive “prophylactic” DLI begin-
ning on day 35 posttransplantation in an eff o rt to convert
their state of mixed chimerism to a state of full donor
hematopoiesis.
Unmobilized donor leukocytes were obtained by leuka-
p h e resis using a Cobe Spectra cell (Cobe Laboratories, Lake-
wood, CO) separator a c c o rding to the manufacture r ’s instru c-
tions. All products were pro c u red by peripheral venous
access. Pheresis durations w e re 120 to 240 minutes and
yielded a median of 1.4 × 1 08 mononuclear cells per kg
recipient body weight (range, 0.7 to 2.0 × 1 08) and 0.8 × 1 08
C D 3+ T cells per kg recipient body weight (range, 0.3 to 1.1 ×
1 08). Donor leukaphereses were initially perf o rmed on days 35
and 56; fresh leukocytes were either immediately infused into
recipients or collected and infused on day 35, with the re m a i n-
der cry o p re s e rved for later infusion. In some cases (ie, for
donors who lived a long distance from the transplant center),
donor leukocytes were collected and cry o p re s e rved short l y
after bone marrow harvest. The target number of CD3+
T cells per infusion for prophylactic DLI was 1 × 1 07/ k g .
Higher numbers of CD3+ T cells were given in some cases for
t reatment of relapse, and in 1 instance, 5 × 1 07 C D 3+ T c e l l s /
kg were given in a prophylactic DLI on day 56.
S u p p o rt i v e Care
Patients were cared for in either high-efficiency part i c u l a t e
air (HEPA ) - fil t e red or laminar air flow rooms. All patients had
triple-lumen Silastic central venous catheters. Anti-infective
m e a s u res included co-trimoxazole for Pneumocystis carinii p ro-
phylaxis from admission until day –1, then 3 times per week
after resolution of neutropenia; ofloxacin 400 mg twice per day
or levofloxacin 500 mg daily until resolution of neutropenia;
fluconazole beginning on day –1 at a dose of 400 mg, which
was reduced to 200 mg daily on day 0; and intravenous (IV)
acyclovir at a dose of 250 mg/m2 e v e ry 8 hours beginning on
day –1, which was changed to a dose of 400 mg twice per day
after resolution of neutropenia. Febrile neutropenia was tre a t e d
with bro a d - s p e c t rum antibacterial agents, usually vancomycin
and ceftazidime. All blood products were irradiated with 2500
cGy using a cesium irradiator and were transfused through a
t h i rd-generation leukocyte depletion fil t e r.
Antiemetic therapy consisted of dexamethasone 20 mg
I V, granisetron 1 mg IV twice per day or ondansetron 24 mg
IV daily, diphenhydramine 25 to 50 mg IV, and lorazepam
1 mg IV before each dose of cyclophosphamide. D i p h e n h y-
dramine and lorazepam were given as needed for nausea or
v o m i t i n g .
Treatment of acute GVHD consisted of corticosteroids
(IV methylprednisolone, which was changed to oral methyl-
prednisolone when patients could tolerate oral medications),
initially at a dose of 1 to 2 mg/kg and then tapered as toler-
ated. Anti–interleukin-2 receptor (Zenapax; Hoff m a n n -
LaRoche, Nutley, NJ) or anti-CD2 (Biotransplant, Boston,
MA) monoclonal antibody therapy was given to 5 patients
for steroid-resistant disease.
A n a l yses of Chimerism
Analyses of microsatellite variable-number- o f - t a n d e m -
repeat (VNTR) or short - t a n d e m - repeat markers were per-
f o rmed on peripheral blood leukocytes from patients and
their donors before BMT. Weekly microsatellite analyses
were then performed on peripheral blood leukocytes begin-
ning on day 7 through day 100 posttransplantation and on
days 28 and 100 on bone marrow aspirate samples. Periph-
eral blood analyses were then perf o rmed every 6 months
beginning on day 180 posttransplantation. Micro s a t e l l i t e
analyses were performed using a standard technique [27,28]. 
Statistical Anal y s i s
The Kaplan-Meier method was used to estimate dis-
e a s e - f ree and overall survival probability for patients who
underwent transplantation [29].
RESULTS
Patient Enr o l l m e n t
All 21 enrolled patients who had a genotypically or phe-
notypically HLA-identical donor received their intended
transplant (see Table 1). Twenty of the 21 patients had expe-
rienced a chemotherapy-re f r a c t o ry relapse of their malig-
n a n c y. The remaining patient experienced an untre a t e d
relapse 11 months after an autologous stem cell transplant. 
E n g r a f t m e n t
Median time to absolute neutrophil count greater than
0.5 × 1 09/L was 12 days (range, 10-20 days). Median time to
a platelet  count of greater than 20 × 1 09/L in 17 of
2 1 patients was 16 days (range, 8-30 days). In 2 patients with
p ro g ressive acute leukemia, platelet counts had not re c o v e re d
at 76 and 121 days posttransplantation. In 2 patients with
H o d g k i n ’s  disease, platelet counts never fell below 20 ×
1 09/L, and platelet transfusions were not re q u i red (Table 2).
In 18 of 20 evaluable patients, donor hematopoiesis (as
defined by >1% donor cells in the peripheral blood) was
o b s e rved until at least day 35 posttransplantation. Three of
the 18 patients, however, lost evidence of donor hemato-
poiesis, 1 on day 42, 1 on day 43, and 1 on day 45 post-
transplantation. 
Engraftment Syndr o m e
Fourteen of 21 patients developed signs and symptoms
consistent with engraftment syndrome [30]. This syndrome
occurred shortly before or coincident with engraftment and
was characterized by fever, weight gain, and a pre d o m inantly
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t runcal and facial erythematous rash. In each case histo-
pathologic analysis of skin biopsy samples was not diagnostic
of acute GVHD, and the syndrome responded promptly to
corticosteroids. 
Six of the 14 patients who developed engraftment syn-
d rome were ultimately believed to have grade II or gre a t e r
GVHD. Four of 8 patients without GVHD showed no sign of
GVHD after a rapid taper of their immunosuppressive med-
ication (ie, cyclosporine and cort i c o s t e roids), and they were
able to receive a DLI beginning at 5 weeks posttransplantation. 
G r a f t - V ersus-Host Disease
In the absence of grade II or ≥ grade II GVHD (or the
absence of initial suspicion of GVHD), cyclosporine was
tapered and discontinued at a median of 37 days (range, 19-
154 days) posttransplantation. The median duration of
cyclosporine therapy for all 21 patients was 67 days (range,
19-301 days) posttransplantation.
Six of 21 patients (29%) developed biopsy-confirm e d
grade II or greater GVHD after BMT and before DLI,
often during the rapid cort i c o s t e roid taper that followed
treatment of the initial signs and symptoms of engraftment
syndrome. In 5 of the 6 patients, the grade II GVHD was
limited to the skin. One patient (5%) developed grade IV
GVHD involving both the skin and gastrointestinal (GI)
tract. An additional 5 patients developed grade II or greater
acute GVHD after prophylactic DLI, and 1 patient devel-
oped de novo grade IV GVHD after DLI for treatment of
posttransplantation relapse.
Donor Leukocyte Infusions
P rophylactic DLIs, beginning 5 to 6 weeks post BMT,
w e re given to 10 patients (Table 3). Six patients received a
single DLI consisting of 1 × 1 07/kg CD3+ T cells on day 35,
and 4 patients received a DLI (1 × 1 07/kg CD3+ T cells) on
day 35 and a second DLI (1 × 1 07/kg CD3+ T cells [n = 3] and
Table 2. Posttransplantation Patient Outcomes*
Median Days toP r e v i o u s C y M a x i m u m
A g e , R e m i s s i o n A u t o l o g o u s D o s e , A N C P C P r e - D L I O r g a n ( s )
U P N D i s e a s e y S t a t u s S T C m g / k g T I > 0 . 5 > 2 0 , 0 0 0 GVHD Grade A f f e c t e d R e s p o n s e O u t c o m e
181 T-cell rich 41 RR N 200 Y 15 23 0 CR Died day 180, 
B-cell lymphoma GVHD (post-DLI)
194 Lymphomatoid 44 RR N 200 Y 16 8 I Skin PR Died day 193, PD
granulomatosis
201 B-cell DLCL 45 RR N 200 N 17 15 II Skin PR Died day 518, PD
218 AML 44 RR N 200 Y 18 >76 II Skin PR Died day 76, PD
234 B-cell DLCL 22 RR N 200 N 18 17 0 CR Alive day 560 in CCR
021 Follicular mixed-cell 35 RR Y 150† N 12 30 0 CR Alive day 548 in CCR 
lymphoma
238 Hodgkin’s  disease 27 UR Y 200 N 10 11 II Skin CR Alive day 520 with PD
247 AML 27 RR N 200 Y 18 22 IV Skin, Gut CR Died day 77, PTLD
254 Hodgkin’s  disease 27 RR N 150‡ N 20 14 0 PR Died day 167, PD
259 T-cell ALL 40 RR N 150‡ Y 15 10 0 PD Died day 36, PD
268 CLL 55 RR N 150‡ Y 13 15 II Skin PR Alive day 343 in PR
275 Follicular small 43 RR N 150‡ Y 12 12 0 CR Alive day 329 with PD
cleaved-cell 
l y m p h o m a
279 B-cell DLCL 62 RR N 150‡ Y 12 12 II Skin PD Died day 51, PD
282 Diffuse mixed-cell 57 RR N 150‡ Y 11 14 0 PD Died day 43, PD
lymphoma
283 AML 44 RR N 150‡ N 12 NE 0 PD Alive day 273 with PD
285 CLL 50 RR N 150‡ N 14 24 0 CR Alive day 267 in CCR
317 B-cell DLCL 39 RR N 150‡ Y 14 15 0 PD Died day 90 with PD
322 Follicular mixed-cell 50 RR N 150‡ Y 14 14 0 NR Alive day 127
lymphoma
328 T-cell rich B-cell 61 RR N 150‡ Y 9 9 0 PR Alive day 110
lymphoma
329 Hodgkin’s  disease 55 RR N 150‡ N 10 —§ 0 CR Alive day 105 in CCR
334 Hodgkin’s  disease 24 RR Y 150‡ N 14 —§ 0 NE Alive day 85
*ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; ANC, absolute neutrophil count; CCR, continuous complete response;
CLL, chronic lymphocytic leukemia; CR, complete response; Cy, cyclophosphamide; DLCL, diffuse large-cell lymphoma; DLI, donor leukocyte
infusion; GVHD, graft-versus-host disease; NE, not evaluable; NR, no response; PC, platelet count; PD, progressive disease; PR, partial response;
PTLD, posttransplantation lymphoproliferative disease; RR, refractory relapse; SCT, stem cell transplantation; TI, thymic irradiation; UPN, unique
patient number; UR, untreated relapse.
†Cyclophosphamide dose reduced to 150 mg/kg because of cardiac toxicity.
‡Cyclophosphamide dose reduced to 150 mg/kg because of change in protocol.
§Platelets never fell below 20 × 109/L, and platelet transfusions were not required.
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5 × 1 07/kg CD3+ T cells [n = 1]) between days 56 and 64 post-
transplantation. In 6 patients, the mixed chimeric state con-
v e rted to a state of full donor hematopoiesis at a median of 5
weeks (range, 2-8 weeks) after 1 (n = 3) or 2 (n = 3) DLIs.
In 3 of the 4 evaluable recipients of a single pro p h y l a c t i c
DLI, conversion to full donor chimerism occurred within 2
to 5 weeks. In the remaining patient, stable mixed chimerism
was maintained 8 weeks after DLI. Two patients who re c e i v e d
a single DLI were not evaluable. One (unique patient number
[UPN] 317) showed increasing donor hematopoiesis after a
single prophylactic DLI and received a second DLI on day 49
for disease pro g ression; the other (UPN 334) had not yet
been evaluated 5 weeks post-DLI. Grade II or gre a t e r
GVHD developed in 3 patients who received a single DLI; 2
patients developed grade II skin GVHD that improved after
an increase in cyclosporine dose or initiation of low-dose cor-
t i c o s t e roids, and the third patient experienced grade III
GVHD of the skin and GI tract. 
In 3 of the 4 patients who received 2 DLIs, conversion
to full donor chimerism occurred between 5 and 8 weeks
post-DLI. Severe (grade IV) acute GVHD led to the death
of 1  patient (UPN 181) after 2 DLIs (1 × 1 07 C D 3+
T cells/kg at 5 weeks and 5 × 1 07 C D 3+ T cells/kg at
8 weeks); one patient (UPN 254) developed grade IV
GVHD that improved with cort i c o s t e roids and anti–IL-2
receptor monoclonal antibody therapy. One patient (UPN
234) did not develop acute GVHD but had biopsy evidence
of chronic GVHD of the liver on day 421 posttransplanta-
tion. The fourth patient (UPN 322) had no detectable
donor cells 1 week after receiving the first prophylactic DLI
and received a second DLI on day 64; donor cells remained
undetectable 8 weeks after the second DLI.
An additional 4 patients received either 2 or 3 DLIs for
t reatment of posttransplantation relapse. One of these
patients (UPN 194) had an undetectable level of donor
chimerism at the time of his relapse on day 44 posttransplan-
tation. One DLI of approximately 5 × 1 07 C D 3+ T c e l l s / k g
was given on day 49, resulting in prompt re g ression of his
lymphoma and the de novo appearance of a donor- d e r i v e d
band on VNTR analysis of his blood, indicating the pre s e n c e
of approximately 1% donor chimerism. A second DLI of 5 ×
1 07 C D 3+ T cells/kg on day 121 was followed by conversion
to >99% donor chimerism and the development of grade IV
GVHD. Although the clinical manifestations of the patient’s
GVHD resolved after treatment with cort i c o s t e roids, cyclo-
sporine, and ATG, he developed a fulminant re c u rrence of his
lymphoma and died on day 193 posttransplantation. In
another patient (UPN 201), non-Hodgkin’s  lymphoma
showed a mixed response after 3 DLIs—given on days 142,
187, and 230—and had symptoms associated with chro n i c
GVHD-like clinical manifestations (eg, rash and keratocon-
junctivitis sicca). The patient died from pro g ressive pul-
m o n a ry lymphoma on day 518 posttransplantation. One
patient (UPN 238) received 3 DLIs for relapsed Hodgkin’s
disease. After the third DLI, given in conjunction with
recombinant interf e ron alfa, this patient developed grade II
cutaneous GVHD and demonstrated conversion from 60% to
>99% donor cells. No antitumor response was observed in 1
patient with acute myeloid leukemia (AML) (UPN 283) after
2 DLIs for pro g ressive disease.
Chimerism Studies
Eighteen of 20 evaluable patients developed persistent
mixed lymphohematopoietic chimerism after BMT, as defin e d
by >1% donor peripheral blood white blood cells until at least
day 35 posttransplantation (the day of the initial pro p h y l a c t i c
DLI). One patient (UPN 259) experienced early pro g re s s i o n
of his acute lymphoblastic leukemia, and chimerism studies
w e re not obtained after day 27 posttransplantation. 
The pattern of chimerism as determined by microsatel-
lite analysis of peripheral blood over time in 10 recipients of
either 1 or 2 prophylactic DLIs is illustrated in Figure 1. A
fall in the percentage of donor cells shortly after engraft-
ment can be seen in the majority of cases. Six of 8 evaluable
patients (followed for at least 8 weeks after initial DLI)
demonstrated conversion to full donor hematopoiesis.
Seven pat ients with a diagnosis other than acute
leukemia did not receive DLI for chimerism conversion.
Table 3. Prophylactic DLI and Patient Outcome*
% Donor Chimerism GVHD
UPN Day(s) of DLI Before DLI After DLI Time, wk† Pre-DLI Post-DLI Response
181 35, 56 30-70 99 5 0 IV CR
234 35, 62 50-70 >99 8 0 —‡ CR
254 36, 57 1-10 >99 7 0 IV PR
322 36, 64 10-30 <1 8 0 0 PR
021 35 50-70 >99 4 0 0 CR
285 37 30-70 >99 2 0 II CR
329 41 30-50 >99 5 0 II CR
317§ 35 50-70 70-90 2 0 NE PD
328 40 30-70 30-50 8 0 0 PR
334 44 10-30 30-50 2 I III NE
*CR indicates complete response; DLI, donor leukocyte infusion; GVHD, graft-versus-host disease; NE, not evaluable; PD, progressive disease;
PR, partial response.
†Time in weeks after initial DLI or until conversion to >99% donor hematopoiesis.
‡Limited chronic GVHD.
§Patient subsequently received a second DLI (6 × 107 CD3+ cells/kg) for progressive disease on day 49 and could not be evaluated for chimerism
conversion or postprophylactic DLI GVHD.
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T h ree patients (UPNs 282, 194, and 275) had nonde-
tectable (<1%) donor chimerism by days 28, 34, and 43,
re s p e c t i v e l y, posttransplantation. Three patients (UPNs
238, 268, and 279) maintained a state of stable mixed lym-
phohematopoietic chimerism. Two patients (UPNs 194 and
238) demonstrated conversion to full donor chimerism after
DLI for disease relapse. Spontaneous conversion to full
donor chimerism occurred by day 91 posttransplantation in
1 patient (UPN 201). 
The median percentage of donor cells present over time
in 10 patients who received prophylactic DLI and in 8 of the
11 patients who did not receive DLI because of the pre s e n c e
or initial suspicion of acute GVHD is illustrated in Figure 2.
T h ree patients with acute leukemia were excluded from the
data used for this graph because they either did not achieve
remission or had early disease pro g ression; thus, the contri-
bution from host leukemic cells to the cell populations ana-
lyzed complicated the interpretation of their chimerism data. 
Transplant-Related To x i c i t i e s
T h ree patients (UPNs 21, 181, and 285) developed
cyclophosphamide-induced cardiac toxicity, which included a
significant decrease in left ventricular ejection fraction
( LVEF) and the development of atrial fibrillation in 2 patients
(UPNs 181 and 285) with symptoms and signs of congestive
h e a rt failure. One of the latter 2 patients (UPN 285) still had
persistent left ventricular dysfunction and was re c e i v i n g
digoxin, metoprolol, and milrinone 9 months posttransplan-
tation. A third patient (UPN 21) had chest tightness with
ischemic electro c a rdiographic changes (ie, T-wave inversions
in lateral leads) and a fall in LVEF from 46% to 39%. 
Because of severe AT G - related toxicities, including
hypotension,  renal  insuff i c i e n c y, and shock liver  in
2 patients, ATG dose was reduced to 15 mg/kg (based on
ideal or actual body weight, whichever was less). The timing
of ATG was also changed in an attempt to reduce the inci-
dence of acute GVHD (from days –2, –1, and 1 to days –1,
1, 3, and 5). No serious toxicities occurred after the reduc-
tion of ATG dose from 30 to 15 mg/kg.
One patient (5%) died from a transplantation-re l a t e d
complication. After treatment with high-dose cort i c o-
s t e roids, cyclosporine, and anti–interleukin-2 re c e p t o r
monoclonal antibody therapy for grade IV GVHD, this
patient (UPN 247) with AML died on day 77 posttransplan-
tation because of a widely disseminated B-cell non-Hodgk-
i n ’s  lymphoma. A second patient (UPN 181) developed
grade IV GVHD after a second prophylactic DLI (5.0 × 107
C D 3+ cells/kg) and died on day 180 from pro g re s s i v e
hepatic failure and polymicrobial sepsis.
Response 
F o u rteen of 20 evaluable patients (70%) achieved a
response; 8 responses were complete, and 6 were partial (see
Table 2). Of 13 evaluable patients with chemotherapy-re f r a c-
t o ry non-Hodgkin’s  or Hodgkin’s  lymphoma who under-
went BMT, 6 achieved a complete response and 4 a part i a l
response. Of 9 evaluable patients who received pro p h y l a c t i c
DLI, 5 (56%) achieved a complete response, compared with
3 of 11 patients (27%) who did not receive prophylactic DLI.
The computed tomography scans and bone marro w
biopsy specimens shown in Figures 3 and 4 illustrate the
striking antitumor responses in patients with advanced
c h ronic lymphocytic leukemia (CLL) and re f r a c t o ry non-
Hodgkin’s  lymphoma. One patient (UPN 268) with chemo-
t h e r a p y - re f r a c t o ry CLL had a peripheral white blood cell
count of 29,800/µL (80% lymphocytes), massive mediastinal
and intra-abdominal lymphadenopathy, and splenomegaly
( F i g u re 3A). He received an HLA-matched donor marro w
transplant and achieved near-complete remission of his dis-
ease. Figure 3B shows resolution of his intra-abdominal
lymphadenopathy and splenomegaly, and B cells were still
declining at follow-up, as shown in Figure 3C. He has no
evidence of disease progression on day 343 posttransplanta-
tion but has chronic cutaneous GVHD.
Figure 1. The pattern of chimerism as determined by microsatellite analysis of peripheral blood over time in 6 patients who received a single prophylactic DLI
beginning on day 35 (one patient [UPN 317] was included until day 49, when DLI was given for relapse) (A) and in 4 patients who received 2 prophylactic DLIs
(B). Black arrows indicate time of DLI administration. 
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The pre- and posttransplantation bone marrow biopsy
specimens pictured in Figure 4 show resolution of diff u s e
marrow involvement by a follicular mixed large- and small-
cell lymphoma in 1 patient (UPN 21). This patient had pre-
viously received an autologous stem cell transplant for
relapse of stage IV disease. He then experienced a second
relapse and received an HLA-matched donor transplant
under our protocol for his pro g ressive, chemotherapy-
re f r a c t o ry disease. On day 35 posttransplantation, he
received prophylactic DLI, which led to conversion to full
donor chimerism within 4 weeks, without the development
of GVHD. He is presently disease free and was without evi-
dence of GVHD on day 548 posttransplantation.
S u rv i v a l
Eleven of the 21 patients (52%) were alive at a median of
445 days (range, 105-548 days) posttransplantation; 7 of these
w e re free of disease pro g ression. Two patients, UPNs 247 and
18, died from tre a t m e n t - related complications on days 77 and
180, re s p e c t i v e l y. Eight patients (5 patients with non-Hodgkin’s
lymphoma, 2 with acute leukemia, and 1 with Hodgkin’s  dis-
ease) died from pro g ressive malignancy posttransplantation.
Kaplan-Meier graphs of pro g re s s i o n - f ree and overall surv i v a l
p robability for the 21 patients who underwent transplantation
a re shown in Figures 5 and 6, re s p e c t i v e l y. 
DISCUSSION
Treatment options for patients with chemotherapy- and
r a d i o t h e r a p y - re f r a c t o ry hematologic malignancies are very
limited. Early transplantation series using conventional
myeloablative preparative regimens demonstrated long-
t e rm disease-free survival rates of ≤15% for this group of
patients [31-33]. Although more recent series have shown
an apparent improvement in the outcome of patients with
advanced hematologic malignancies [34,35], the surv i v a l
p robabilities for patients with chemotherapy-re f r a c t o ry dis-
ease remain poor.
This trial has demonstrated for the first time the ability to
intentionally achieve stable mixed lymphohematopoietic
chimerism after conditioning with a nonmyeloablative chemo-
therapy regimen that includes pretransplantation thymic irr a-
diation and peritransplantation anti–T-cell antibody therapy.
Although cyclophosphamide conditioning (with or without
ATG) has been used in patients undergoing transplantation
for severe aplastic anemia and hematologic malignancies and
appears to be sufficient to achieve donor engraftment in the
majority of cases [9,36], documentation of sustained mixed
chimerism is lacking. Our regimen differs significantly fro m
p revious regimens in both the treatment scheme (ie, post-
transplantation ATG and thymic irradiation) and intent (ie,
intentional induction of mixed chimerism to diminish the toxi-
city of host conditioning, to ameliorate GVHD, and to enable
subsequent administration of DLI).
Based on a murine model that showed that anti–T- c e l l
antibodies are still circulating at the time of transplantation,
and there f o re deplete donor T cells in vivo, posttransplantation
ATG was used in an attempt to deplete donor T cells in vivo.
With the establishment of a mixed chimeric state in the mouse,
DLI in doses that would cause severe GVHD in freshly mye-
loablated recipients can be given later, without causing signifi-
cant GVHD [7,8]. Elimination of recipient-type hematopoietic
cells after DLI, without development of GVHD, is evidence
that a graft-versus-host reaction can be confined to the lym-
Figure 2. The median percentage of donor cells found in peripheral white blood cells over time in 10 recipients of an HLA-matched donor BMT who received
DLI beginning on day 35 and between days 56 and 64 posttransplantation, and 8 patients who did not receive DLI posttransplantation because of the presence or
suspicion of GVHD. Patterns of chimerism were determined by microsatellite analysis and are shown as estimates of the percentage of donor DNA present. 
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phohematopoietic system, a situation that is desirable to
achieve GVL effects without the development of GVHD.
Although the outcome of our trial re flects some of the same
results obtained in the murine model, the initial GVHD
o b s e rved in some patients indicates that posttransplantation
ATG does not deplete donor T cells in humans to the same
extent as in the mouse. Nevertheless, the conversion to full
donor chimerism after 1 DLI in 3 of the 4 patients evaluated,
without the development of acute GVHD in 1 patient and with
t re a t m e n t - responsive GVHD limited to the skin in 2 patients,
is evidence that a similar phenomenon can be seen in humans.
In addition, the achievement of complete remission in these 3
patients is evidence that GVL effects can be achieved in this
manner without the development of severe GVHD.
After a series of protocol revisions intended to re d u c e
t r a n s p l a n t a t i o n - related morbidity, including a reduction in
cyclophosphamide dose and a change in the dosing and tim-
ing of ATG, the present regimen has been very well toler-
ated. These protocol changes were necessitated by card i a c
toxicity in 2 patients who received a cyclophosphamide dose
of 200 mg/kg, unexpectedly severe AT G - related toxicities
that occurred in 2 patients who received ATG in a dose of
30 mg/kg, and the desire to reduce toxicity in this group of
heavily pretreated patients, many of whom had received pre-
vious mediastinal radiation therapy. Furthermore, we sought
to further reduce the risk of GVHD by administering an
i n c reased pro p o rtion of the ATG posttransplantation in
recipients of the modified regimen.
F i g u r e 3. Pretransplantation (A) and day 100 posttransplantation (B) computed tomography (CT) scans of the abdomen in a patient (UPN 268) with CLL and
lymphadenopathy and splenomegaly. Pretransplantation CT scan shows massive intra-abdominal lymphadenopathy and splenomegaly. Day 100 posttransplantation
CT scan demonstrates resolution of the intra-abdominal lymphadenopathy and splenomegaly. C, Declining B-cell population over time in the same patient. Total
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P resently the most prominent and common toxicity after
transplantation is engraftment syndrome, which occurred in
14 of 21 patients, often early posttransplantation (as early as
day 7). Cytokine-mediated engraftment syndromes have been
described pre v i o u s l y, including a “hyper-acute GVHD syn-
d rome” that occurred after HLA-mismatched donor trans-
plantation [30,37]. Manifestations of this syndrome, however,
w e re exquisitely sensitive to cort i c o s t e roids in most of our
patients, thereby allowing an early and rapid taper of immuno-
s u p p ressive therapy. GVHD could not be confirmed in biopsy
specimens obtained while patients had this syndrome, and in
m o re than half of patients, no definitive evidence of GVHD
developed after discontinuation of the steroids. 
Weekly determinations of lymphohematopoietic
chimerism in our trial allowed evaluation of the relationship
of host and donor cell populations to the engraftment
p rocess. The curious fall in the percentage of donor cells
shortly after engraftment in most cases could signify a tran-
sient host-versus-graft reaction, which might pro v i d e
cytokines that contribute to the clinical syndrome observed
or may reflect the recovery of host hematopoietic cells after
conditioning. Thus, donor hematopoietic cells may become
“diluted” by recovering host elements. 
Recently the results of pilot clinical trials using nonmye-
loablative preparative strategies for HLA-matched donor
allogeneic BMT have been published [20-22]. Patients with
various hematologic malignancies have received flu d a r a b i n e
or low-dose busulfan-based regimens and allogeneic BMT.
The tolerability of these regimens is evidenced by the accept-
able toxicities that have been observed, even in older patients
and in patients with comorbid illnesses. I n f requently per-
f o rmed chimerism analyses, however, have shown a pre d o m i-
nance of donor chimerism in most cases. A high pro b a b i l i t y
of relapse has been re p o rted in 1 of the series [20], and fol-
low-up durations in these studies have been short .
The role of thymic irradiation in induction of the
mixed chimeric state in this clinical trial is unclear. In the
murine models of Sharabi and Sachs [3] and Pelot et al. [7],
thymic irradiation was a critical component, as it eliminated
a l l o reactive host thymocytes that could mediate intrathymic
rejection of donor cells and prevent the establishment of a
mixed chimeric state. However, the role of thymocytes in
resisting establishment of a mixed chimeric state in adult
humans is questionable. Only 13 of the 21 patients re c e i v e d
thymic irradiation; the other patients had received pre v i o u s
mediastinal radiation therapy, possibly ablating whatever
thymic function may have been present pre v i o u s l y. There
has been no obvious diff e rence in the establishment of a
mixed chimeric state or in the incidence or severity of
GVHD among recipients of HLA-matched or -mismatched
donor marrow to whom thymic irradiation was or was not
a d m i n i s t e re d .
The striking antitumor responses in most patients with
c h e m o t h e r a p y - re f r a c t o ry hematologic malignancies appear
to be largely a result of a GVL effect. Most patients in this
trial previously received and were resistant to cyclophos-
phamide, the only cytore d u c t i v e agent used in our condi-
tioning regimen. In patients with easily measurable disease
Figure 4. Pretransplantation (A) and posttransplantation (B) bone marrow biopsy specimens in 1 patient (UPN 21). The pretransplantation specimen demon-
strates hypercellularity with diffuse involvement by predominantly small to medium-sized cleaved lymphoma cells. The posttransplantation (day 106) specimen
shows trilineage hematopoiesis with no evidence of lymphoma.
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(eg, palpable lymphadenopathy or skin lesions), antitumor
responses were not maximal until after engraftment had
been achieved or even after DLI. Although there was a sug-
gestion of an increased complete response rate after prophy-
lactic DLI, the number of patients in each group was too
small to reach a meaningful conclusion. More o v e r, acute
GVHD was a common accompaniment of pro p h y l a c t i c
DLI. The impact of DLI on patient response rate and pro-
g re s s i o n - f ree and overall survival will there f o re have to be
addressed in future prospective, randomized trials. Because
early relapses occurred in 5 of these 21 patients with aggres-
sive hematologic malignancies, further eff o rts will be
required to determine which patients are not likely to bene-
fit from a strategy using a nonmyeloablative chemothera-
peutic preparative regimen and immunotherapy with post-
transplantation DLI.
Despite this favorable early experience with deliberate
induction of mixed chimerism after nonmyeloablative trans-
plant preparative therapy, several problems remain. First,
the incidence of GVHD does not appear to be significantly
different (and may even be higher when GVHD after DLI
is included) from that after conventional allogeneic stem cell
transplantation using myeloablative conditioning therapy.
Consideration is therefore being given to the substitution of
a monoclonal anti–T-cell antibody for ATG (which may
effect a more significant T-cell depletion in vivo and elimi-
nate potential AT G - related toxicities). Second, the timing,
and perhaps the dosing, of DLI may be suboptimal. In most
situations, cyclosporine had not been completely tapered by
day 35, the intended day of the first DLI in our study. In 2
of 3 cases in which a second DLI was given on day 56,
severe GVHD developed. In our current protocol the sec-
ond DLI is omitted, given the observation that the full
effects of DLI, in terms of both GVHD and GVL, may not
be seen for many weeks after an infusion [38]. Finally,
efforts are under way to determine the cellular mechanisms
of GVHD and GVL in this mixed chimeric model so that
the dissociation of the 2 can be maximized.
In summary, a state of mixed lymphohematopoietic
chimerism is reliably induced after a novel nonmyeloablative
p reparative regimen and BMT from an HLA-matched
related donor. DLI can often be given 5 weeks after BMT to
p romote conversion from the mixed chimeric state to a state
of full donor chimerism and thereby more fully capture the
i m p o rtant GVL effects of these transplants. This is possible
without induction of GVHD. This regimen also appears to
be well tolerated, even among heavily pre t reated patients
with advanced disease. Although this treatment strategy
shows considerable promise in the treatment of patients with
c h e m o t h e r a p y - re f r a c t o ry hematologic malignancy, its role in
specific diseases and the role of prophylactic DLI in aug-
menting a GVL effect remain to be determined. 
ACKNOWLEDGMENTS
This work was supported in part by National Institutes
of Health grants 1RO1 CA79986-01A1, 1RO1 CA79988-
01A1, 1RO1 CA79989-01A1, and 1RO1 HL63430-01.
REFERENCES
1. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allo-
geneic or xenogeneic bone marrow leads to specific acceptance of
F i g u r e 5. Kaplan-Meier progression-free survival probability for the
21 recipients of an HLA-matched donor bone marrow transplantation. 
Figure 6. Kaplan-Meier overall survival probability for the 21 recipients of an HLA-matched donor bone marrow transplantation.
Intentional Induction of Mixed Chimerism for Refractory Hematologic Malignancies 
allografts or xenografts. Nature. 1984;30:168-170.
2. Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Stephany D,
Sachs DH. Effect of selective T cell depletion of host and/or
donor bone marrow lymphopoietic repopulation, tolerance, and
graft-versus-host disease in mixed allogeneic chimeras (B10 +
B10.D2-B10). J Immunol. 1984;136:28-33.
3. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific
transplantation tolerance induced by a non lethal preparative regi-
men. J Exp Med. 1989;169:493-502.
4. Sharabi Y, Abraham VS, Sykes M, Sachs DH. Mixed allogeneic
chimeras prepared by a non-myeloablative regimen: requirement
for chimerism to maintain tolerance. Bone Marrow Transplant.
1992;9:191-197.
5. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic
chimerism and renal allograft tolerence in cynomolgus monkeys.
Transplantation. 1995;59:256-252.
6. Sykes M, Szot GL, Swenson K, Pearson DA. Induction of high
levels of allogeneic hematopoietic reconstitution and donor-spe-
c i fic tolerance without myelosuppressive conditioning. Nat Med.
1997;3:783-787.
7. Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang Y-G,
Sykes M. Lymphohematopoietic graft-vs.-host reactions can be
induced without graft-vs.-host disease in murine mixed chimeras
established with a cyclophosphamide-based nonmyeloablative
conditioning regimen. Biol Blood Marrow Transplant. 1999;5:133-
143.
8. Sykes M, Sheard MA, Sachs DH. Graft-versus-host-related
immunosuppression is induced in mixed chimeras by allore-
sponses against either host or donor lymphohematopoietic cells.
J Exp Med. 1988;168:2391-2396.
9 . Hill RS, Petersen FB, Storb R, et al. Mixed hematologic chimerism
after allogeneic marrow transplantation for severe aplastic anemia is
associated with a higher risk of graft rejection and a lessened inci-
dence of acute graft-versus-host disease. B l o o d. 1986;67:811-816.
10. Durnam DM, Anders KR, Fisher L, O’Quigley J, Bryant EM,
Thomas ED. Analysis of the origin of marrow cells in bone mar-
row transplant recipients using a Y-chromosome–specific in situ
hybridization assay. Blood. 1989;74:2220-2226.
11. Roy DC, Tantravahi R, Murray C, et al. Natural history of mixed
chimerism after bone marrow transplantation with CD6-depleted
allogeneic marrow: a stable equilibrium. Blood. 1990;75:296-304.
12. Roux E, Helg C, Chapuis B, Jeannet M, Roosnek E. Evolution of
mixed chimerism after allogeneic bone marrow transplantation as
determined on granulocytes and mononuclear cells by the poly-
merase chain reaction. Blood. 1992;79:2775-2783.
13. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman
JM. Competitive polymerase chain reaction to estimate the num-
ber of BCR-ABL transcripts in chronic myeloid leukemia patients
after bone marrow transplantation. Blood. 1993;82:1929-1936.
14. Colby C, Sykes M, Sachs DH, Spitzer TR. Cellular modulation
of acute graft-versus-host disease. Biol Blood Marrow Transplant.
1997;3:287-293.
15. Frassoni F, Strada P, Sessarego M, et al. Mixed chimerism after
allogeneic bone marrow transplantation for leukemia: correlation
with dose of total body irradiation and graft-versus-host disease.
Bone Marrow Transplant. 1990;5:235-240.
16. Chalmers EA, Sproul AM, Mills KI, et al. Effect of radiation on
the development of mixed haemopoietic chimerism following T
cell-depleted allogeneic bone marrow transplantation. Bone Mar -
row Transplantation. 199210:425-430.
17. Bertheas MF, Lafage M, Levy P, et al. Influence of mixed
chimerism on the results of allogeneic bone marrow transplanta-
tion for leukemia. Blood. 1991;78:3103-3106.
1 8 . Huss R, Deeg JH, Gooley T, et al. Effect of mixed chimerism on
graft-versus-host disease, disease recurrence and survival after HLA-
identical marrow transplantation for aplastic anemia or chronic
myelogenous leukemia. Bone Marrow Transplant. 1 9 9 6 ; 1 8 : 7 6 7 - 7 7 6 .
19. Petz LD, Yam P, Wallace RB, et al. Mixed hematopoietic
chimerism following bone marrow transplantation for hemato-
logic malignancies. Blood. 1987;70:1331-1337.
20. Giralt SE, Estey E, Albitar M, et al. Engraftment of allog e n e i c
hematopoietic progenitor cells with purine analog-containing
chemotherapy: harnessing graft-versus-leukemia without mye-
loablative therapy. Blood. 1997;89:4531-4536.
21. Khouri IF, Keating M, Korbling M, et al. Transplant-Lite: induc-
tion of graft-versus-malignancy using fludarabine-based nonabla-
tive chemotherapy and allogeneic blood progenitor-cell trans-
plantation as treatment for lymphoid malignancies. J Clin Oncol.
1998;16:2817-2824.
22. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem
cell transplantation and cell therapy as an alternative to conven-
tional bone marrow transplantation with lethal cytoreduction for
the treatment of malignant and nonmalignant hematologic dis-
eases. Blood. 1998;91:756-763.
23. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induc-
tion of graft-versus-host disease as immunotherapy for relapsed
chronic myeloid leukemia. N Engl J Med. 1994;330:100-106.
24. Mackinnon S, Papadopoulo EB, Carabasi MH, et al. Adoptive
immunotherapy evaluating escalating doses of donor leukocytes
for relapse of chronic myeloid leukemia following bone marrow
transplantation: separation of graft-versus-leukemia responses
from graft-versus-host disease. Blood. 1995;86:1261-1268.
25. Kolb H, Holler E. Adoptive immunotherapy with donor lympho-
cyte transfusions. Curr Opin Oncol. 1997;9:139-145.
2 6 . Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaematopoietic
chimerism and graft-versus-host lymphoma effects after non-
myeloblative therapy and HLA-mismatched transplantation.
L a n c e t. 1999;353:1755-1779.
27. Schultze JL, Cardoso AA, Freeman GL, et al. Follicular lym-
phomas can be induced to present alloantigen efficiently: a con-
ceptual model to improve their tumor immunogenicity. Proc Natl
Acad Sci U S A. 1995;92:8200-8204.
28. Nakao S, Nakatsumi T, Chuhjo T, et al. Analysis of late graft fail -
ure after allogeneic bone marrow transplantation: detection of
residual host cells using amplification of variable number of tan-
dem repeats loci. Bone Marrow Transplant. 1992;9:107-111.
29. Kaplan EL, Meier P: Nonparametric estimation from incomplete
observations. J Am Stat Assoc. 1958;53:457-481.
30. Cahill RA, Spitzer TR, Mazumder A. Marrow engraftment and
clinical manifestations of capillary leak syndrome. Bone Marrow
Transplant. 1996;18:177-184.
3 1 . Report from the International Bone Marrow Transplant Registry.
Advisory Committee of the International Bone Marrow Transplant
Registry. Bone Marrow Transplant. 1 9 8 9 ; 4 : 2 2 1 - 2 2 8 .
32. Sullivan KM, Witherspoon RP, Storb R, Buckner CD, Sanders J,
Thomas ED. Long-term results of allogeneic bone marrow trans-
plantation. Transplant Proc. 1989;21(1 pt 3):2926-2928.
3 3 . Thomas E, Buckner C, Banaji M, et al. One hundred patients with
acute leukemia treated by chemotherapy, total body irradiation,
and allogeneic marrow transplantation. B l o o d. 1977;49:511-533.
34. Long GD, Amylon MD, Stockerl-Goldstein KE, et al. Fraction-
ated total-body irradiation, etoposide, and cyclophosphamide fol-
T.R. Spitzer et al.
lowed by allogeneic bone marrow transplantation for patients
with high-risk or advanced-stage hematological malignancies. Biol
Blood Marrow Transplant. 1997;3:324-330.
35. Giralt SA, LeMaistre CF, Vriesendrop HM, et al. Etoposide,
cyclophosphamide, total-body irradiation, and allogeneic bone
marrow transplantation for hematologic malignancies. J Clin
Oncol. 1994;12:1923-1930.
36. Santos GW, Sensenbrenner LL, Burke PJ, et al. The use of
cyclophosphamide for clinical marrow transplantation. Transplant
Proc. 1972;4:559-564.
37. Powles RL, Morgenstern GR, Kay HE, et al. Mismatched family
donor for bone marrow transplantation and acute leukemia.
Lancet. 1983;1:612-615.
38. Lokhorst HM, Schattenberg A, Cornelissen JJ. Donor leukocyte
infusions are effective in relapsed multiple myeloma after allo-
geneic bone marrow transplantation. Blood. 1997;90:4206-4211.
